Noble Financial Reiterates Outperform Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “outperform” rating reissued by Noble Financial in a report issued on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other research firms also recently weighed in on GOVX. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $80.00.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock traded up $0.00 during trading on Tuesday, reaching $0.43. 212,837 shares of the company traded hands, compared to its average volume of 2,041,380. The firm has a market capitalization of $3.20 million, a PE ratio of -0.04 and a beta of 3.66. GeoVax Labs has a 1-year low of $0.43 and a 1-year high of $17.74. The company has a 50 day moving average price of $0.75 and a 200-day moving average price of $1.27.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19. Equities research analysts expect that GeoVax Labs will post -4.94 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.